When combining baseline ALT level, combined treatment of first anti-HLH regimen and subsequent anti-lymphoma regimen, treatment response, and ENKL or ANKL subtype in multivariate analysis, elevated baseline ALT level was the independent risk factor of OS (P=0.025). This evidence concerns the gene GPT and lymphoma.